Verified· 3 sources

Vaccentis AG

Summary

About the company

The core activity of Vaccentis AG is the development of tumor vaccines, particularly through the use of the individualized precision immunotherapy platform AIPI (ALL INDIVIDUALIZED PRECISION IMMUNOTHERAPY TUMOUR VACCINE TECHNOLOGY PLATFORM).

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

✓ Offered3

Tumor vaccines

Protein-based tumor vaccines for the development of cancer immunotherapies; focus on individualized precision immunotherapy and the AIPI tumor vaccine technology platform.

Adjuvant therapy of renal cell carcinoma (VCC-001)

Adjuvant treatment of renal cell carcinoma with the lead candidate VCC-001; with clinical data from Phase III, evidence of efficacy and a safety profile.

Development of additional tumor vaccine candidates

Research and preclinical development of additional indications with VCC-002 for metastatic renal cell carcinoma as well as VCC-003, VCC-004 and VCC-005 for other cancer types.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Vaccentis AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

Vaccentis AG

About the company

Products & services

Looking for direct email addresses and phone numbers?

Media

No knowledge articles yet

Vaccentis AG in comparison

Industry comparisons are coming soon

Similar companies